Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer

<p>Consort diagram of the study.Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.</p>

Guardado en:
Detalles Bibliográficos
Autor principal: Carlotta Antoniotti (15352506) (author)
Otros Autores: Alessandra Boccaccino (15352509) (author), Robert Seitz (15352512) (author), Mirella Giordano (15352515) (author), Aurélie Catteau (15352518) (author), Daniele Rossini (15086287) (author), Filippo Pietrantonio (15035729) (author), Lisa Salvatore (15352521) (author), Kimberly McGregor (15352524) (author), Francesca Bergamo (15352527) (author), Veronica Conca (15352530) (author), Simone Leonetti (15352533) (author), Federica Morano (14937009) (author), Giorgio Papiani (15352536) (author), Emiliano Tamburini (15352539) (author), Maria Bensi (15352542) (author), Sabina Murgioni (15352545) (author), Douglas Teller Ross (15352548) (author), Alessandro Passardi (15352551) (author), Isabelle Boquet (15352554) (author), Tyler J. Nielsen (15352557) (author), Jérôme Galon (15031113) (author), Matthew Gordon Varga (15352560) (author), Brock L. Schweitzer (15352563) (author), Chiara Cremolini (15352566) (author)
Publicado: 2025
Materias:
Cancer
Tumor Biology
Cancer Detection and Diagnosis
Therapeutic Research and Development
Immuno-oncology
Biomarkers
Gastrointestinal Cancers
Colorectal cancer
Immunotherapy
Biomarkers for immunotherapy
Translational Research
Tumor Microenvironment
Immune cells and the microenvironment
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:<p>Consort diagram of the study.Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.</p>

Ejemplares similares